Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis

Anna Sandström Gerdtsson, Christer Wingren, Helena Persson, Payam Delfani, Malin Nordström, He Ren, Xin Wen, Ulrika Ringdahl, Carl A.K. Borrebaeck, Jihui Hao

    Research output: Contribution to journalArticle

    13 Scopus citations

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors.

    Original languageEnglish (US)
    Pages (from-to)1305-1316
    Number of pages12
    JournalMolecular oncology
    Volume10
    Issue number8
    DOIs
    StatePublished - Oct 1 2016

      Fingerprint

    Keywords

    • Antibody microarrays
    • Biomarker signatures
    • Early detection
    • Pancreatic cancer
    • Recombinant antibodies

    ASJC Scopus subject areas

    • Molecular Medicine
    • Genetics
    • Oncology
    • Cancer Research

    Cite this

    Gerdtsson, A. S., Wingren, C., Persson, H., Delfani, P., Nordström, M., Ren, H., Wen, X., Ringdahl, U., Borrebaeck, C. A. K., & Hao, J. (2016). Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis. Molecular oncology, 10(8), 1305-1316. https://doi.org/10.1016/j.molonc.2016.07.001